{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:29:05Z","timestamp":1793651345275,"version":"4.5.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)","id":[{"id":"https:\/\/ror.org\/01zgy1s35","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00198-026-08127-x","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T09:22:52Z","timestamp":1783502572000},"page":"2439-2449","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Romosozumab in severe postmenopausal osteoporosis\u2014real-world data from 192 women"],"prefix":"10.1007","volume":"37","author":[{"given":"Nicolas","family":"Dehne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6586-6794","authenticated-orcid":false,"given":"Felix N.","family":"von Brackel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"G\u00fcnzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Barvencik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9449-5013","authenticated-orcid":false,"given":"Ralf","family":"Oheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"issue":"9319","key":"8127_CR1","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/S0140-6736(02)08657-9","volume":"359","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, Melton LJ (2009) Epidemiology and outcomes of osteoporotic fractures. The Lancet 359(9319):1761\u20131767. https:\/\/doi.org\/10.1016\/S0140-6736(02)08657-9","journal-title":"The Lancet"},{"key":"8127_CR2","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532\u20131543. https:\/\/doi.org\/10.1056\/NEJMoa1607948","journal-title":"N Engl J Med"},{"key":"8127_CR3","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S et al (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412\u2013420. https:\/\/doi.org\/10.1056\/NEJMoa1305224","journal-title":"N Engl J Med"},{"key":"8127_CR4","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML et al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417\u20131427. https:\/\/doi.org\/10.1056\/NEJMoa1708322","journal-title":"N Engl J Med"},{"key":"8127_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2025.117701","volume":"202","author":"E Gielen","year":"2026","unstructured":"Gielen E, Amini N, Coppens D et al (2026) Bone mineral density response to romosozumab in post-menopausal women: a prospective observational real-world study. Bone 202:117701. https:\/\/doi.org\/10.1016\/j.bone.2025.117701","journal-title":"Bone"},{"issue":"12","key":"8127_CR6","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1007\/s00198-025-07722-8","volume":"36","author":"G Adami","year":"2025","unstructured":"Adami G, Bartezaghi M, Montanari F et al (2025) ROMosozumab early experience in female patients with severe osteoporosis in an Italian real-world setting, the ROMEO study. Osteoporosis Int. 36(12):2459\u20132469. https:\/\/doi.org\/10.1007\/s00198-025-07722-8","journal-title":"Osteoporosis Int."},{"key":"8127_CR7","doi-asserted-by":"publisher","unstructured":"von Brackel FN, Dehne N, Kornak U et al (2026) Romosozumab is effective in patients with variants in LRP5, LRP6, or WNT1. Osteoporos Int. https:\/\/doi.org\/10.1007\/s00198-026-07932-8","DOI":"10.1007\/s00198-026-07932-8"},{"key":"8127_CR8","doi-asserted-by":"publisher","first-page":"12S","DOI":"10.1097\/00007632-199712151-00003","volume":"22","author":"DL Glaser","year":"1997","unstructured":"Glaser DL, Kaplan F (1997) Osteoporosis. Definition and clinical presentation. Spine 22:12S-16S. https:\/\/doi.org\/10.1097\/00007632-199712151-00003","journal-title":"Spine"},{"issue":"4","key":"8127_CR9","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/jbmr.1580","volume":"27","author":"EM Lewiecki","year":"2012","unstructured":"Lewiecki EM, Laster AJ, Miller PD, Bilezikian JP (2012) More bone density testing is needed, not less. J Bone Miner Res 27(4):739\u2013742. https:\/\/doi.org\/10.1002\/jbmr.1580","journal-title":"J Bone Miner Res"},{"issue":"5","key":"8127_CR10","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s00198-014-2655-z","volume":"25","author":"ES Siris","year":"2014","unstructured":"Siris ES, Adler R, Bilezikian J et al (2014) The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporosis Int 25(5):1439\u20131443. https:\/\/doi.org\/10.1007\/s00198-014-2655-z","journal-title":"Osteoporosis Int"},{"key":"8127_CR11","doi-asserted-by":"publisher","unstructured":"Shuhart CR, Yeap SS, Anderson PA et al (2019) Executive summary of the 2019 ISCD Position Development Conference on monitoring treatment, DXA cross-calibration and least significant change, spinal cord injury, peri-prosthetic and orthopedic bone health, transgender medicine, and pediatrics. J Clin Densitom 22(4):453-471. https:\/\/doi.org\/10.1016\/j.jocd.2019.07.001","DOI":"10.1016\/j.jocd.2019.07.001"},{"issue":"6","key":"8127_CR12","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00223-023-01143-7","volume":"113","author":"M Bartosik","year":"2023","unstructured":"Bartosik M, Simon A, Strahl A, Oheim R, Amling M, Schmidt FN (2023) Comparison of motion grading in 1,000 patients by first- and second-generation HR-pQCT: a propensity score matched cohort study. Calcif Tissue Int 113(6):597\u2013608. https:\/\/doi.org\/10.1007\/s00223-023-01143-7","journal-title":"Calcif Tissue Int"},{"issue":"9","key":"8127_CR13","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1007\/s00198-020-05438-5","volume":"31","author":"DE Whittier","year":"2020","unstructured":"Whittier DE, Boyd SK, Burghardt AJ et al (2020) Guidelines for the assessment of bone density and microarchitecture in vivo using high-resolution peripheral quantitative computed tomography. Osteoporosis Int 31(9):1607\u20131627. https:\/\/doi.org\/10.1007\/s00198-020-05438-5","journal-title":"Osteoporosis Int"},{"issue":"7","key":"8127_CR14","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1002\/jbmr.3128","volume":"32","author":"SL Manske","year":"2017","unstructured":"Manske SL, Davidson EM, Burt LA, Raymond DA, Boyd SK (2017) The estimation of second-generation HR-pQCTFrom first-generation HR-pQCT using in vivo cross-calibration. J Bone Miner Res 32(7):1514\u20131524. https:\/\/doi.org\/10.1002\/jbmr.3128","journal-title":"J Bone Miner Res"},{"key":"8127_CR15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/1471-2105-7-123","volume":"7","author":"HJ Motulsky","year":"2006","unstructured":"Motulsky HJ, Brown RE (2006) Detecting outliers when fitting data with nonlinear regression \u2013 a new method based on robust nonlinear regression and the false discovery rate. BMC Bioinformatics 7:123. https:\/\/doi.org\/10.1186\/1471-2105-7-123","journal-title":"BMC Bioinformatics"},{"issue":"6","key":"8127_CR16","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nm.1963","volume":"15","author":"T Schinke","year":"2009","unstructured":"Schinke T, Schilling AF, Baranowsky A et al (2009) Impaired gastric acidification negatively affects calcium homeostasis and bone mass. Nat Med 15(6):674\u201381. https:\/\/doi.org\/10.1038\/nm.1963","journal-title":"Nat Med"},{"issue":"11","key":"8127_CR17","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s00198-023-06867-8","volume":"34","author":"D Fitzpatrick","year":"2023","unstructured":"Fitzpatrick D, Lannon R, Laird E et al (2023) The association between proton pump inhibitors and hyperparathyroidism: a potential mechanism for increased fracture\u2014results of a large observational cohort study. Osteoporosis Int 34(11):1917\u20131926. https:\/\/doi.org\/10.1007\/s00198-023-06867-8","journal-title":"Osteoporosis Int"},{"key":"8127_CR18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.bone.2017.07.005","volume":"103","author":"H Ishibashi","year":"2017","unstructured":"Ishibashi H, Crittenden DB, Miyauchi A et al (2017) Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: a phase 2 study. Bone 103:209\u2013215. https:\/\/doi.org\/10.1016\/j.bone.2017.07.005","journal-title":"Bone"},{"issue":"1","key":"8127_CR19","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s11657-025-01598-1","volume":"20","author":"J Everts-Graber","year":"2025","unstructured":"Everts-Graber J, Ferrari S, Popp A et al (2025) Early transition from short-term romosozumab to antiresorptive therapies: analysis of 26 cases. Arch Osteoporos 20(1):106. https:\/\/doi.org\/10.1007\/s11657-025-01598-1","journal-title":"Arch Osteoporos"},{"issue":"3","key":"8127_CR20","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S2213-8587(25)00319-5","volume":"14","author":"BZ Leder","year":"2026","unstructured":"Leder BZ, Ramchand SK, Jordan M (2026) 3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial. Lancet Diabetes Endocrinol 14(3):216\u2013222. https:\/\/doi.org\/10.1016\/S2213-8587(25)00319-5","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"8127_CR21","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jocd.2017.07.004","volume":"21","author":"S Promma","year":"2018","unstructured":"Promma S, Sritara C, Wipuchwongsakorn S et al (2018) Errors in patient positioning for bone mineral density assessment by dual X-ray absorptiometry: effect of technologist retraining. J Clin Densitom 21(2):252\u2013259. https:\/\/doi.org\/10.1016\/j.jocd.2017.07.004","journal-title":"J Clin Densitom"},{"issue":"1","key":"8127_CR22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00198-002-1316-9","volume":"14","author":"R Hasserius","year":"2003","unstructured":"Hasserius R, Karlsson MK, Nilsson BE, Redlund-Johnell I, Johnell O (2003) Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: a 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study. Osteoporos Int 14(1):61\u201368. https:\/\/doi.org\/10.1007\/s00198-002-1316-9","journal-title":"Osteoporos Int"},{"issue":"3","key":"8127_CR23","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1359\/jbmr.081103","volume":"24","author":"P Chen","year":"2009","unstructured":"Chen P, Krege JH, Adachi JD et al (2009) Vertebral fracture status and the World Health Organization risk factors for predicting osteoporotic fracture risk. J Bone Miner Res 24(3):495\u2013502. https:\/\/doi.org\/10.1359\/jbmr.081103","journal-title":"J Bone Miner Res"},{"issue":"3","key":"8127_CR24","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00198-003-1514-0","volume":"15","author":"O Johnell","year":"2004","unstructured":"Johnell O, Kanis JA, Od\u00e9n A et al (2004) Fracture risk following an osteoporotic fracture. Osteoporos Int. 15(3):175\u2013179. https:\/\/doi.org\/10.1007\/s00198-003-1514-0","journal-title":"Osteoporos Int."},{"issue":"4","key":"8127_CR25","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1359\/jbmr.2000.15.4.721","volume":"15","author":"CM Klotzbuecher","year":"2000","unstructured":"Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15(4):721\u201339. https:\/\/doi.org\/10.1359\/jbmr.2000.15.4.721","journal-title":"J Bone Miner Res"},{"issue":"5","key":"8127_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2021.105219","volume":"88","author":"K Ebina","year":"2021","unstructured":"Ebina K, Tsuboi H, Nagayama Y et al (2021) Effects of prior osteoporosis treatment on 12-month treatment resonse of romosozumab in patients with postmenopausal osteoporosis. Joint Bone Spine 88(5):105219. https:\/\/doi.org\/10.1016\/j.jbspin.2021.105219","journal-title":"Joint Bone Spine"},{"key":"8127_CR27","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.bone.2015.07.036","volume":"81","author":"C Graeff","year":"2015","unstructured":"Graeff C, Campbell Pena J et al (2015) Administration of romosozumab improves vertebral trabecular and cortical bone as assessed with quantitative computed tomography and finite element analysis. Bone 81:364\u2013369. https:\/\/doi.org\/10.1016\/j.bone.2015.07.036","journal-title":"Bone"},{"issue":"8","key":"8127_CR28","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/jbmr.3452","volume":"33","author":"MR McClung","year":"2018","unstructured":"McClung MR, Brown JP, Diez-Perez A et al (2018) Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study. J Bone Miner Res 33(8):1397\u20131406. https:\/\/doi.org\/10.1002\/jbmr.3452","journal-title":"J Bone Miner Res"},{"issue":"9","key":"8127_CR29","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/jbmr\/zjae112","volume":"39","author":"FH Glorieux","year":"2024","unstructured":"Glorieux FH, Langdahl B, Chapurlat R et al (2024) Setrusumab for the treatment of osteogenesis imperfecta: 12-month results from the phase 2b asteroid study. J Bone Miner Res 39(9):1215\u20131228. https:\/\/doi.org\/10.1093\/jbmr\/zjae112","journal-title":"J Bone Miner Res"},{"key":"8127_CR30","doi-asserted-by":"crossref","unstructured":"Ni X, Zhang Z, Guan W et al (2023) Shift in calcium from peripheral bone to axial bone after tumor resection in patients with tumor-induced osteomalacia. J Clin Endocrinol Metab.108(11):e1365-e1373. http:\/\/doi.org\/10.1210\/clinem\/dgad252","DOI":"10.1210\/clinem\/dgad252"},{"key":"8127_CR31","doi-asserted-by":"publisher","unstructured":"Schmidt FN, Delsmann J, Yazigi B et al (2024) Approaching virtual osteoid volume estimation and in-depth tissue characterization in patients with tumor-induced osteomalacia. J Bone Miner Res. 39(2):116-129. https:\/\/doi.org\/10.1093\/jbmr\/zjae008","DOI":"10.1093\/jbmr\/zjae008"},{"issue":"5","key":"8127_CR32","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00223-024-01290-5","volume":"115","author":"FN von Brackel","year":"2024","unstructured":"von Brackel FN, Grambeck J, Barvencik F, Amling A, Oheim R (2024) MTX osteopathy versus osteoporosis including response to treatment data-a retrospective single center study including 172 patients. Calcif Tissue Int 115(5):599\u2013610. https:\/\/doi.org\/10.1007\/s00223-024-01290-5","journal-title":"Calcif Tissue Int"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08127-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-08127-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08127-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:02:08Z","timestamp":1793048528000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-08127-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["8127"],"URL":"https:\/\/doi.org\/10.1007\/s00198-026-08127-x","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"9 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ND and CG have no conflict of interest. FvB has recieved a speakers fee from UCB.\u00a0FB has received speaker fees from Alexion, UCB, and DiaSorin and has received institutional research grants from UCB and Alexion. RO has served as a speaker and advisory board member for Kyowa Kirin, Inozyme, Ipsen, Pharmacosmos, UCB, and Mereo and has received an institutional research grant from Kyowa Kirin, UCB, and Inozyme.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}